Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 13, Issue 15, 2007, Pages 4448-4455

  Byrd, John C ^a,h   O'Brien, Susan ^b   Flinn, Ian W ^c   Kipps, Thomas J ^d   Weiss, Mark ^e   Rai, Kanti ^f   Lin, Thomas S ^a   Woodworth, James ^g   Wynne, Dee ^g   Reid, Jennifer ^g   Molina, Arturo ^g   Leigh, Bryan ^g   Harris, Sarah ^g  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^g BIOGEN   (United States)

^h OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD23 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANISETRON; IMMUNOGLOBULIN G1 ANTIBODY; LUMILIXIMAB; MONOCLONAL ANTIBODY CD23; RITUXIMAB; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIAPHORESIS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; HYPOXIA; LEUKOPENIA; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NOSE CONGESTION; OPTIMAL DRUG DOSE; PARAINFLUENZA VIRUS INFECTION; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; RECEPTOR OCCUPANCY; RECURRENT CANCER; REFRACTORY CANCER; RELAPSE; RIGOR; SIDE EFFECT; SKIN ALLERGY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, IGE; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34547691135     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1463     Document Type: Article

References (31)

1. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
2. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004;163-183.
3. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999;91:861-8.
4. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.
5. Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988;30:457-9.
6. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347:1432-8.
7. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-25.
8. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7.
9. Flinn IW, Kumm E, Grever MR, et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. Blood 2004;104:139a-475.
10. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91.
11. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64.
12. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-51.
13. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70.
14. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
15. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88.
16. Keating M J, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
17. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
18. Pathan N, Chu P, Scales L, et al. IDEC-152 (anti-CD23) induced apoptosis in CLL cells is mediated by caspase activation and downmodulation of anti-apoptotic proteins. Blood 2002;100:803a, #3170.
19. Pathan N, Zou A, Wynne D, et al. Lumiliximab (IDEC-152) an anti-CD23 antibody, induces apoptosis in vitro and in vivo in CLL cells. Blood 2003;102:438a-1596.
20. Mangiola M, Welsh K, Kitada S, et al. Anti-CD20 antibody rituximab and anti-CD23 antibody IDEC-152 induce apoptosis of malignant B-cells in combination with chemical antagonists of XIAP. Blood 2004;104:393a-1401.
21. Pathan N, Hariharan K, Berquist L, et al. Induction of apoptosis by IDEC-152 (anti-CD23) in chronic lymphocytic leukemia. Proc Am Assoc Cancer Res 2002;1005, #4982.
22. Chu P, Scales L, Zou A, et al. Mechanism of IDEC-152-induced apoptosis in chronic lymphocytic leukemia B cells. Proc Am Assoc Cancer Res (2nd ed) 2003;126-7, #661.
23. Pathan N, Hariharan K, Hopkins M, et al. Induction of apoptosis by IDEC-152 (anti-CD23) in lymphoma cells. Blood 2001;98:367a, #1545.
24. Rosenwasser LJ, Busse WW, Lizambri RG, et al. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 2003;112:563-70.
25. Matutes E, Polliack A. Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:22-47.
26. Hopkins MT, Pathan N, Chu P, et al. IDEC-152 (anti-CD23) triggers apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro. Blood 2002;100:597a, #2346.
27. Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003;63:36-8.
28. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755-62.
29. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002;94:2033-9.
30. Keating M , Manshouri T, O'Brien S, et al. A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia (CLL). Blood 2002;100:205a, #771.
31. Byrd JC, Castro J, O'Brien S, et al. Comparison of results from a phase 1/2 study of Lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood 108, No.11, abstract 32, pp.130, 200.